• Mon, January 27, 2025

by: MSN

MP Materials' SWOT analysis: rare earth stock's vertical integration strategy

MP Materials Corp. (NYSE:MP), the largest rare earth producer outside of China and currently valued at $3.48 billion, is positioning itself as a key player in the global rare earth elements (REE) market through its vertically integrated mine-to-magnet strategy.

by: CoinTelegraph

Apple closes up amid US tech stock washout from China AI startup DeepSeek

Apple was one of the few "magnificent seven" tech stocks that withstood a broader market fallout spurred by Chinese AI firm DeepSeek's latest model.

by: MSN

Got $3,000? 2 Monster Growth Stocks to Buy Right Now Without Hesitation

Do not wait for the right time to invest. Invest when you have money. If you have $3,000 to invest, these stocks could be bought right now. The post Got $3,000? 2 Monster Growth Stocks to Buy Right Now Without Hesitation appeared first on The Motley Fool Canada.

by: MSN

TKO Group Holdings CEO Emanuel Ariel acquires $47.9 million in stock

Emanuel Ariel, the Chief Executive Officer of TKO Group Holdings, Inc. (NYSE:TKO), has recently acquired a significant amount of the company's Class A Common Stock. According to a recent SEC filing, Ariel purchased shares worth approximately $47.

by: MSN

Brokers just upgraded these 3 ASX stocks to buys

It's bullish ratings galore for investors this week. The post Brokers just upgraded these 3 ASX stocks to buys appeared first on The Motley Fool Australia.

by: MSN

Karyopharm Therapeutics' SWOT analysis: biotech stock faces pivotal year

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a biotechnology company focused on developing novel cancer treatments, stands at a critical juncture as it navigates through a challenging biotech landscape while advancing its pipeline of promising drug candidates.
  • Tue, January 28, 2025

by: FXStreet

Why China's DeepSeek is causing Bitcoin and crypto market to plunge

Bitcoin (BTC) slipped below $100,000 on Monday as China-based artificial intelligence (AI) model DeepSeek began gaining popularity across the US market, overtaking OpenAI's ChatGPT. DeepSeek's impact also led to rapid declines in the stock market with NASDAQ — spearheaded by Nvidia — diving more than 3%.

by: Investing

Here's why DeepSeek is weighing on power stocks

Investing.com -- DeepSeek, a Chinese AI model, is disrupting power and energy infrastructure stocks. Analysts at BMO Capital Markets note that DeepSeek's high efficiency and low energy consumption are key factors.

by: Reuters

US tech stock tumble highlights risk of market reliance on megacaps

Turbulence in some of the biggest tech names is reminding investors of one of the major risks to the U.S. stock market's record-setting rally: Reliance on a handful of mammoth companies to power those gains.

by: NewsNation

What is a robo-advisor and should you get one?

Robo-advisors must register with the U.S. Securities and Exchange Commission (SEC) and follow the same laws and regulations that a traditional human broker would. Most robo-advisors are also members of the Financial Industry Regulatory Authority (FINRA).

by: MSN

Why Nvidia, Microsoft, and other US artificial intelligence (AI) stocks just crashed

Unexpected results from an AI upstart have sent these stocks reeling. The post Why Nvidia, Microsoft, and other US artificial intelligence (AI) stocks just crashed appeared first on The Motley Fool Australia.

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Applied Digital Corporation in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Core Scientific, Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of MGO Global, Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of RF Acquisition Corp. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Gorilla Technology Group Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of CalEthos Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of SiTime Corporation in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Xiao-I Corporation in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Innoviz Technologies Ltd. in recent trading

by: WOPRAI

獁漠⁦慊㠲桴‬〲㔲‬桴牥⁥慨⁳敢湥猠扵瑳湡楴污猠汥楬杮漠⁦教扲썡₩牂湡獤䌠牯⹰椠敲散瑮琠慲楤杮

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Cipher Mining Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of NeoVolta Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Nukkleus Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Solid Power, Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Tecogen Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Hallador Energy Company in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of TravelSky Technology Limited in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of LuxUrban Hotels Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Maris-Tech Ltd. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Inno Holdings Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of VCI Global Limited in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of SenseTime Group Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of WiMi Hologram Cloud Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Bluesky Digital Assets Corp. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Bridger Aerospace Group Holdings, Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of U Power Limited in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Immutable Holdings Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Mullen Automotive, Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of J-Long Group Limited in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of EVgo, Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of MicroCloud Hologram Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Nxu, Inc. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Arax Holdings Corp. in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Autris in recent trading

by: WOPRAI

As of Jan 28th, 2025, there has been substantial selling of Dunxin Financial Holdings Limited in recent trading

by: WOPRAI

131 Earnings Releases for Jan 28th, 2025

Karyopharm Therapeutics' SWOT analysis: biotech stock faces pivotal year

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a biotechnology company focused on developing novel cancer treatments, stands at a critical juncture as it navigates through a challenging biotech landscape while advancing its pipeline of promising drug candidates.
The article from MSN Money discusses a SWOT analysis of Karyopharm Therapeutics, a biotechnology company, as it navigates a pivotal year. Karyopharm focuses on developing treatments for cancer and other serious diseases, with its lead drug, selinexor, approved for multiple myeloma. Strengths include its innovative approach to nuclear export inhibitors and a robust pipeline. Weaknesses are highlighted by the limited market penetration of selinexor due to its side effects and competition from other myeloma treatments. Opportunities for Karyopharm include expanding selinexor's indications, potential partnerships, and exploring new markets. However, threats loom with patent cliffs, regulatory challenges, and the high costs associated with drug development. The article emphasizes that 2024 could be a defining year for Karyopharm as it seeks to broaden its market presence and manage its financial runway amidst these challenges.

Read the Full MSN Article at:
https://www.msn.com/en-us/money/general/karyopharm-therapeutics-swot-analysis-biotech-stock-faces-pivotal-year/ar-AA1xYaXw

Like: 👍